REFERENCES

• KendlerKS.PrescottCA.A population-based twin study of lifetime major depression in men and women. Arch Gen Psychiatry19995639449892254
   PubMed Web of Science ®Google Scholar
• CoyneJC.Fechner-BatesS.SchwenkTL.Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry199416267276
   PubMed Web of Science ®Google Scholar
• StoudemireA.FrankR.HedemarkN.KamletM.BlazerDG.The economic burden of depression. Gen Hosp Psychiatry19868387394
   Google Scholar
• PattenSB.Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2.J Affect Dis200163354111246078
   PubMed Web of Science ®Google Scholar
• BlazerDG.Mood disorders: Epidemiology. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, PA: Lippincott Williams & Williams.200012981307
   Google Scholar
• EatonWW.KramerM.AnthonyJC.DrymanA.ShapiroS.LockeBZ.The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psych Scand198979163
   PubMed Web of Science ®Google Scholar
• HagnellO.LankeJ.RorsmanB.OjesjoL.Are we entering an age of melancholy? Depressive illnesses in a prospective study epidemiological study over 25 years: the Lundby Study.Psychol Med1982122792897100351
   PubMed Web of Science ®Google Scholar
• LoftisJM.HauserP.The phenomenology and treatment of interferoninduced depression. J Affect Disord20048217519015488246
   PubMed Web of Science ®Google Scholar
• AsnisGM.De La GarzaR.2nd Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol20064032233516633105
   PubMed Web of Science ®Google Scholar
• SchaeferM.EngelbrechtMA.GutO.et al.Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry20022673174612188106
   PubMed Web of Science ®Google Scholar
• TraskPC.EsperP.RibaM.RedmanB.Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol20001823162610829053
   PubMed Web of Science ®Google Scholar
• RaisonCL.DemetrashviliM.CapuronL.MillerAH.Neuropsychiatrie adverse effects of interferon-alpha: recognition and management. CNS Drugs20051910512315697325
   PubMed Web of Science ®Google Scholar
• ReichenbergA.GormanJM.DieterichDT.Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS200519S174S17816251815
   PubMed Web of Science ®Google Scholar
• DieperinkE.HoSB.ThurasP.WillenbringML.A prospective study of neuropsychiatrie symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomat200344104112
   PubMed Web of Science ®Google Scholar
• HauserP.KhoslaJ.AuroraH.et al.A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry2002794294712399946
   PubMed Web of Science ®Google Scholar
• CasteraL.ConstantA.HenryC.et al.Impact on adherence and sustained viological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacol Therapeut20062412231230
   PubMed Web of Science ®Google Scholar
• SchaeferM.SchmidtF.HornM.Schmid-WendtnerM-H.VolkenandtM.Depression during treatment with interferon alpha. Psychosomat200445176
   Web of Science ®Google Scholar
• RaisonCL.DemetrashviliM.CapuronL.MillerAH.Neuropsychiatrie adverse effects of interferon-a: recognition and management. CNS Drugs20051910512315697325
   PubMed Web of Science ®Google Scholar
• CotlerSJ.WartelleCF.LarsonAM.GretchDR.JensenDM.CarithersRLJ.Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepatitis20007211217
   PubMed Web of Science ®Google Scholar
• DieperinkE.WillenbringM Ho SB.Neuropsychiatrie symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry200015786787610831463
   PubMed Web of Science ®Google Scholar
• MalaguarneraM.Di FazioI.RestucciaS.PistoneG.FerlitoL.RampelloL.Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiol1998379397
   PubMed Web of Science ®Google Scholar
• CapuronL.HauserP.Hinze-SelchD.MillerAH.NeveuPJ.Treatment of cytokine-induced depression. Brain Behav Immunology200216575580
   PubMed Web of Science ®Google Scholar
• DonnellyS.Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncologic Nursing Forum199825921927
   PubMedGoogle Scholar
• TraskPC.EsperP.RibaM.RedmanB.Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol2000182316232610829053
   PubMed Web of Science ®Google Scholar
• PavolMA.MeyersCA.RexerJL.ValentineAD.MattisPJ.TalpazM.Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurol199545947950
   PubMed Web of Science ®Google Scholar
• MalaguarneraM.LaurinoA.Di FazioI.et al.Neuropsychiatrie effects and type of IFN-a in chronic hepatitis C. J Interferon Cytokine Res20012127327811429157
   PubMed Web of Science ®Google Scholar
• RenaultPF.HoofnagleJH.ParkY.et al.Psychiatric complications of long-term interferon alfa therapy. Arch IntMed198714715771580
   Google Scholar
• CapuronL.GumnickJF.MusselmanDL.et al.Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol200226643652
   PubMed Web of Science ®Google Scholar
• HosodaS.TakimuraH.ShibayamaM.KanamuraH.IkedaK.KumadaH.Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci20005456557211043807
   PubMed Web of Science ®Google Scholar
• BonaccorsoS.MarinoV.BiondiM.GrimaldiF.IppolitiF.MaesM.Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Dis20027223724112450640
   PubMed Web of Science ®Google Scholar
• LinR.RoachE.ZimmermanM.StrasserS.FarrellGC Group) AHCS.Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol1995234874968583134
   PubMed Web of Science ®Google Scholar
• Spath-SchwalbeE.LangeT.PerrasB.FehmHL.BornJ.Interferon-alpha acutely impairs sleep in healthy humans. Cytokine20001251852110857770
   PubMed Web of Science ®Google Scholar
• PoutiainenE.HokkanenL.NiemiM.FarkkilaM.Reversible cognitive decline during high-dose [alpha]-interferon treatment. Pharmacol Biochem Behav1994479019058029260
   PubMed Web of Science ®Google Scholar
• MerimskyO.Reider-GroswasserI.InbarM.ChaitchikS.Interferonrelated mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer1990265966002144747
   PubMed Web of Science ®Google Scholar
• McHutchinsonJG.MannsM.PatelK.et al.Adherence to combination therapy enhances sustained response in genotype-1-infected patents with chronic hepatitis C. Gastroenterol200212210611069
   Google Scholar
• DusheikoG.Side effects of alpha interferon in chronic hepatitis C. Hepatol199726112S121S
   PubMed Web of Science ®Google Scholar
• FontanaRJ.SchwartzSM.GebremariamA.LokASF.MoyerCA.Emotional distress during interferon-a-2B and ribavirin treatment of chronic hepatitis C. Psychosomat200234378385
   Google Scholar
• JanssenH.BrouwerJ.van der MastR.SchalmS.Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol1994212412437989716
   PubMed Web of Science ®Google Scholar
• McHutchisonJG.GordonSC.SchiffER.et al.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med1998339148514929819446
   PubMed Web of Science ®Google Scholar
• EnnsMW.CoxBJ.Personality dimensions and depression: review and commentary. Can J Psychiatry - Revue Canadienne de Psychiatrie199742274284
   PubMed Web of Science ®Google Scholar
• BoyceP.MasonC.An overview of depression-prone personality traits and the role of interpersonal sensitivity. Austr New Zealand J Psychiatry19963090103
   PubMed Web of Science ®Google Scholar
• JoinerTE.Depression in its interpersonal context. In: Gotlieb IH, Hammen CL, eds. Handbook of Depression. New York, NY: Guilford.2002295313
   Google Scholar
• FabregaHJ.Disease and Social Behavior: an Interdisciplinary Perspective. Cambridge, MA: MIT Press.1974
   Google Scholar
• MullenL.S.BlancoC.VaughanSC.VaughanR.RooseSP.Defense mechanisms and personality in depression. Depress Anx199910168174
   PubMed Web of Science ®Google Scholar
• GilbertP.Evolutionary approaches to psychopathology: the role of natural defences. Aust N Z J Psychiatry200135172711270452
   PubMed Web of Science ®Google Scholar
• ParkerG.LipscombeP.The relevance of early parental experiences to adult dependency, hypochondriasis and utilization of primary physicians. Br J Med Psychol1980533553637437356
   PubMed Web of Science ®Google Scholar
• GranekM.Hypochondriasis, acting out and counter-acting out. Br J Med Psychol1989622572642789976
   PubMed Web of Science ®Google Scholar
• HofmannAD.The impact of illness in adolescence and coping behavior. Acta Paediatrica Scand (Supplement)19752562933
   Google Scholar
• ScheurichN.Hysteria and the medical narrative. Persp Biol Med200043461476
   PubMed Web of Science ®Google Scholar
• KihlstromJF.Cantor KihlstromL.Somatization as illness behavior. Adv Mind-Body Med20011724024311931045
   PubMedGoogle Scholar
• MaesM.Psychological stress, cytokines, and the inflammatory response system. Curr Opin Psychiatry199912695700
   Web of Science ®Google Scholar
• SchwarzMJ.ChiangS.MullerN.AckenheilM.T-Helper-1 and T-helper2 responses in psychiatric disorders. Br Behav Immunol200115340370
   PubMed Web of Science ®Google Scholar
• Vollmer-ConnaU.Acute sickness behavior: an immune system-to-brain communication? Psychol Med20013176176711459374
   PubMed Web of Science ®Google Scholar
• MillerGE.RohlederN.StetlerC.et al.Clinical depression and regulation of the inflammatory response during acute stress. Psychosomat Med200567679687
   PubMed Web of Science ®Google Scholar
• PaceTW.MletzkoTC.AlagbeO.et al.Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry20061631630163316946190
   PubMed Web of Science ®Google Scholar
• MorikawaO.SakaiN.ObaraH.SaitoN.Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol19983493173249671113
   PubMed Web of Science ®Google Scholar
• BonaccorsoS.MarinoV.PuzellaA.et al.Increased depressive ratings in patients with hepatitis C receiving interferon-[alpha]-based immunotherapy are related to interferon-[alpha]-induced changes in the serotonergic system. J Clin Psychopharmacol 200222869011799348
   PubMed Web of Science ®Google Scholar
• RoselP.ArranzB.VallejoJ.et al.Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. J Affect Dis19995222523310357037
   PubMed Web of Science ®Google Scholar
• NeumeisterA.KonstantinidisA.StastnyJ.et al.Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry20025961362012090814
   PubMed Web of Science ®Google Scholar
• ShutoH.KataokaY.HorikawaT.FujiharaN.OishiR.Repeated interferon-a administration inhibits dopaminergic neural activity in the mouse brain. Br Res1997747348351
   PubMed Web of Science ®Google Scholar
• SongC.MeraliZ.AnismanH.Variations of nucleus accumbens dopamine and serotonin following systemic interfleukin-1, interleukin-2, or interleukin-6 treatment. Neurosci199988823836
   Web of Science ®Google Scholar
• HanischU-K.QuirionR.Interleukin-2 as a neuroregulatory cytokine. Br Re Rev199621246284
   Google Scholar
• SongC.LinA.BonaccorsoS.et al.The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Dis1998492112199629951
   PubMed Web of Science ®Google Scholar
• KatafuchiT.KondoT.YasakaT.KuboK.TakeS.YoshimuraM.Prolonged effects of polyriboinosinicpolyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neurosci2003120837845
   Web of Science ®Google Scholar
• LicinioJ.WongM-L.Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest1997100294129479399938
   PubMed Web of Science ®Google Scholar
• HansenMK.TaishiP.ChenZ.KruegerJM.Vagotomy blocks the induction of interleukin-1b (IL-1b) mRNA in the brain of rats in response to systemic IL-1b. J Neurosci199818224722539482809
   PubMed Web of Science ®Google Scholar
• YirmiyaR.PollakY.BaakO.et al.Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacol200124531544
   PubMed Web of Science ®Google Scholar
• AnismanH.KokkinidisL.MeraliZ.Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. Br Behav Immunol200216544556
   PubMed Web of Science ®Google Scholar
• LarsonSJ.Behavioral and motivational effects of immune-system activation. J Gene Psychol2002129401414
   Google Scholar
• LarsonSJ.DunnAJ.Behavioral effects of cytokines. Br Behav Immun200115371387
   PubMed Web of Science ®Google Scholar
• DantzerR.AubertA.BlutheR-M.et al.Mechanisms of the behavioral effects of cytokines. Adv Exp Med Biol19994618310610442169
   PubMed Web of Science ®Google Scholar
• DantzerR.KelleyKW.Twenty years of research on cytokine-induced sickness behavior. Br Behav Immun200721153160
   PubMed Web of Science ®Google Scholar
• MaierSF.NguyenKT.DeakT.MilliganED.WatkinsLR.Stress, learned helplessness, and brain interleukin-1b. Adv Exp Med Biol199946123525010442176
   PubMed Web of Science ®Google Scholar
• MakinoM.KitanoY.KomiyamaC.HirohashiM.TakasunaK.Involvement of central opioid systems in human interferon-a induced immobility in the mouse forced swimming test. Br J Pharmacol20001301269127410903965
   PubMed Web of Science ®Google Scholar
• MakinoM.KitanoY.KomiyamaC.TakasunaK.Human interferon-a increases immobility in the forced swimming test in rats. Psychopharmacol2000148106110
   Web of Science ®Google Scholar
• SchrammTM.LawfordBR.MacdonaldGA.CooksleyWG.Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust200017335936111062791
   PubMed Web of Science ®Google Scholar
• GleasonOC.YatesWR.Five cases of interferon-a-induced depression treated with antidepressant therapy. Psychosomat199940510512
   PubMed Web of Science ®Google Scholar
• GleasonOC.YatesWR.IsbellMD.PhilipsenMA.An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry20026319419811926717
   PubMed Web of Science ®Google Scholar
• KrausMR.SchaferA.SchottkerK.et al.Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, doubleblind, placebo-controlled study. Gut20085753153618079286
   PubMed Web of Science ®Google Scholar
• MusselmanDL.LawsonDH.GumnickJF.et al.Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med200134496196611274622
   PubMed Web of Science ®Google Scholar
• GoldmanLS.Successful treatment of interferon-a-induced mood disorders with nortriptyline. Psychosomat199435412413
   PubMed Web of Science ®Google Scholar
• LevensonJL.FallonHJ.Fluoxetine treatment of depression caused by interferon-a. Am J Gastroenterol199388760761 8480744
   PubMed Web of Science ®Google Scholar
• HauserP.SolerR.ReedS.et al.Prophylactic treatment of depression induced by interferon-a. Psychosomat200041439442
   PubMed Web of Science ®Google Scholar
• FarahA.Interferon-induced depression treated with citalopram. J Clin Psychiatry20026316616711874221
   PubMed Web of Science ®Google Scholar
• MorascoBJ.RifaiMA.LoftisJM.IndestDW.MolesJK.HauserP.A randomized trial of paroxetine to prevent interferon-a-induced depression in patients with hepatitis C. J Affect Dis2007103839017292481
   PubMed Web of Science ®Google Scholar
• HorikawaN.YamazakiT.IzumiN.UchiharaM.Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry200325343812583926
   PubMed Web of Science ®Google Scholar
• HauserP.KhoslaJ.AuroraH.et al.A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry2002794294712399946
   PubMed Web of Science ®Google Scholar
• JuenglingFD.EbertD.GutO.et al.Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment. Psychopharmacol2001152383389
   Web of Science ®Google Scholar
• CapuronL.PagnoniG.DemetrashviliM.et al.Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry20055819019616084839
   PubMed Web of Science ®Google Scholar
• AbeS.HoriT.SuzukiT.BabaA.ShiraishiH.YamamotoT.Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochemic Res199924359363
   PubMed Web of Science ®Google Scholar
• CapuronL.NeurauterG.MusselmanDL.et al.Interferon-alpha-induced changes in tryptophan metabolism, relationship to depression and paroxetine treatment. Biol Psychiatry20035490691414573318
   PubMed Web of Science ®Google Scholar
• DunnAL.CrnicLS.Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun199371041118471797
   PubMed Web of Science ®Google Scholar
• WichersMC.MaesM.The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci200429111714719046
   PubMed Web of Science ®Google Scholar
• ChouR.ClarkEC.HelfandM.Screening for Hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Int Med200414046547915023713
   PubMed Web of Science ®Google Scholar
• BaronS.TyringSK.FleischmannWR.The interferons: mechanisms of action and clinical applications. JAMA1991266137513831715409
   PubMed Web of Science ®Google Scholar
• BordenEC.ParkinsonD.A perspective on the clinical effectiveness and tolerance of interferon-(alpha). Sem Oncol19982538
   PubMed Web of Science ®Google Scholar
• MemonMl.MemonMA.Hepatitis C: an epidemiological review. J Viral Hepatitis2002984100
   PubMed Web of Science ®Google Scholar
• WilliamsI.Epidemiology of hepatitis C in the United States. Am J Med19991072S9S10653448
   PubMedGoogle Scholar
• Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.Centers for Disease Control and Prevention, MMWR Recomm Rep199847139
   Google Scholar
• ZdilarD.Franco-BronsonK.BuchlerN.LocalaJA.YounossiZM.Hepatitis C, interferon alfa, and depression. Hepatol20003112071211
   PubMed Web of Science ®Google Scholar
• CasteraL.ConstantA.HenryC.CouzigouP.Psychiatric disorders during treatment of chronic hepatitis C. Gastroenterol Clin Biol20052912313315795658
   PubMedGoogle Scholar
• DanAA.MartinLMC.OngJP.et al.Depression, anemia and healthrelated qulity of life in chronic hepatitis C.J Hepatol200644491498
   Google Scholar
• YounossiZ.KallmanJ.KincaidJ.The effects of HCV infection and management on health-related quality of life. Hepatol200745806816
   PubMed Web of Science ®Google Scholar
• GleasonOC.FucciJC.YatesWR.PhilipsenMA.Preventing relapse of major depression during interferon-a therapy for hepatitis C - a pilot study. Dig Dis Sci2007522557256317436092
   PubMed Web of Science ®Google Scholar
• KrausMR.SchaferA.ScheurlenM.Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med200134537537611484704
   PubMed Web of Science ®Google Scholar
• RaisonCL.WoolwineBJ.DemetrashviliZM.et al.Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacol Therapeut20072511631174
   PubMed Web of Science ®Google Scholar
• SchaeferM.SchwaigerM.GarkishAS.et al.Prevention of interferonalpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol20054279379815885349
   PubMed Web of Science ®Google Scholar
• CuijpersP.SmitF.StratenA.Psychological treatment of subthreshold depression: a systematic review. Acta Psychiatrica Scand2007115434441
   PubMed Web of Science ®Google Scholar
• RovnerBW.CastenRJ.Preventing late-life depression in age-related macular degeneration. Am J Geriatr Psychiatry20081645445918515689
   PubMed Web of Science ®Google Scholar
• MunozRF.LeHL.Ghosh-lppenC.DiazMA.UrizarGG.SotoJ.Prevention of postpartum depression in low-income women: Development of the mams y bebs/mothers and babies course. Cog Behav Practice2007147083
   Web of Science ®Google Scholar
• SchoeversRA.SmitF.DeegDJH.et al.Prevention of late-life depression in primary care: do we know where to begin? Am J Psychiatry20061631611162116946188
   PubMed Web of Science ®Google Scholar
• CapuronL.RavaudA.Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state. N Engl J Med1999340:13709929523
   PubMed Web of Science ®Google Scholar
• RaisonCL.BorisovAS.BroadwellSD.et al.Depression during pegylated interferon-alpha plus ribarin therapy: prevalence and prediction. J Clin Psychiatry200566414815669887
   PubMed Web of Science ®Google Scholar
• LotrichFE.FerrellRE.RabinovitzM.PollockBG.Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry20096534434818801474
   PubMed Web of Science ®Google Scholar
• LotrichFE.RabinovitzF.GirondaP.PollockBG.Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosomat. Res.200763131135
   PubMed Web of Science ®Google Scholar
• FrankE.KupferDJ.PerelJM.CornesC.JarretDB.MallingerAG.Threeyear outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry199047109310992244793
   PubMed Web of Science ®Google Scholar
• GeddesJR.CarneySM.DaviesCH.FurukawaTA.KupferDJ.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet200336165366112606176
   PubMed Web of Science ®Google Scholar
• KleinDN.SantiagoNJ.VivianD.ArnowBA.BlalockJA.DunnerDL.Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consul Clin Psychol200472681688
   PubMed Web of Science ®Google Scholar
• FavaGA.RuiniC.RafanelliC.FinosL.ContiS.GrandiS.Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Arch Gen Psychiatry200416118721876
   Google Scholar
• KrausMR.ShaferA.Al-TaieO.ScheurlenM.Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis20061296100
   Web of Science ®Google Scholar
• CapuronL.RavaudA.MillerAH.DantzerR.Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Br Behav Immunol200418205213
   PubMed Web of Science ®Google Scholar
• FranzenPL.BuysseDJ.RabinovitzM.PollockBG.LotrichFE.Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatric Research2009 In press.
   Web of Science ®Google Scholar
• BuysseDJ.ReynoldsCF.MonkTH.BermanSR.KupferDJ.Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatric Research198928193213
   PubMed Web of Science ®Google Scholar
• FordDE.KamerowDB.Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA1989262147914842769898
   PubMed Web of Science ®Google Scholar
• BreslauN.RothT.RosenthalL.AndreskiP.Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry1996394114188679786
   PubMed Web of Science ®Google Scholar
• RiemannD.VoderholzerU.Primary insomnia: a risk factor to develop depression? J Affect Disord20037625525912943956
   PubMed Web of Science ®Google Scholar
• ChangPP.FordDE.MeadLA.Cooper-PatrickL.KlagMJ.Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study.Am J Epidemiol19971461051149230772
   PubMed Web of Science ®Google Scholar
• FordDE.KamerowDB.Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA1989262147914842769898
   PubMed Web of Science ®Google Scholar
• HorikawaN.YamazakiT.IzumiN.UchiharaM.Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry2003253438
   PubMed Web of Science ®Google Scholar
• MiyaokaH.OtsuboT.KamijimaK.IshiiM.OnukiM.MitamuraK.Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry1999156112010401474
   PubMed Web of Science ®Google Scholar
• KrausMR.SchaferA.FalterH.CsefH.ScheurlenM.Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry20036470871412823087
   PubMed Web of Science ®Google Scholar
• WichersMC.KenisG.LeueC.KoekG.RobaeysG.MaesM.Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry200660777916487941
   PubMed Web of Science ®Google Scholar
• PratherAA.RabinovitzM.PollockBG.LotrichFE.Cytokine-induced depression during IFN-a treatment: the role of IL-6 and sleep quality. Brain Behav Immun2009231109111619615438
   PubMed Web of Science ®Google Scholar
• BullSJ.Huezo-DiazP.BinderEB.et al.Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Mol Psychiatry200814110
   Web of Science ®Google Scholar
• PikeJL.IrwinMR.Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Br Behav Immun200620169174
   PubMed Web of Science ®Google Scholar
• MaesM.MeltzerHY.BosniansE.et al.Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.J Affect Disord1995343013098550956
   PubMed Web of Science ®Google Scholar
• FrommbergerUH.BauerJ.HaselbauerP.FraulinA.RiemannD.BergerM.lnterleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci19972472282339332905
   PubMed Web of Science ®Google Scholar
• SluzewskaA.RybakowskiJ.BosmansE.et al.Indicators of immune activation in major depression. Psychiatry Res1996641611678944394
   PubMed Web of Science ®Google Scholar
• MusselmanDL.MillerAH.PorterMR.et al.Higher than normal plasma interleukin-6 concetrations in cancer patients with depression: preliminary findings.Am J Psychiatry20011581252125711481159
   PubMed Web of Science ®Google Scholar
• DimopoulosN.PiperiC.PsarraV.LeaRW.KalofoutisA.Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res2008161596618783834
   PubMed Web of Science ®Google Scholar
• MarianiE.NeriS.CattiniL.et al.Effect of zinc supplementation on plasma IL-6 and MCP-1 production and NK cell function in healthy elderly: interactive influence of +647 MT1a and -174 IL-6 polymorphic alleles. Exp Gerontol20084346247118215484
   PubMed Web of Science ®Google Scholar
• NicklasBJ.HsuF-C.BrinkleyTJ.et al.Exercice training and plasma C-reactive protein and interleukin-6 in elderly people.J Am Geriatr Soc2008562045205219016938
   PubMed Web of Science ®Google Scholar
• LambertCP.WrightNR.FinckBN.VillarealDT.Exercise but not dietinduced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J App Physiol2008105473478
   PubMed Web of Science ®Google Scholar
• McDonaldEM.MannAH.ThomasHC.Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant a-interferon in hepatitis-B carriers. Lancet198711117511782890808
   PubMedGoogle Scholar
• OtsuboT.MiyaokaH.KamijimaK.OnukiM.IshiiM.MitamuraK.Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi (Jpn)199799101127
   PubMedGoogle Scholar
• LotrichFE.FerrellRE.RabinovitzM.PollockBG.Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry20096534434818801474
   PubMed Web of Science ®Google Scholar
• CapuronL.RaisonCL.MusselmanDL.LawsonDH.NemeroffCB.MillerAH.Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry20031601342134512832253
   PubMed Web of Science ®Google Scholar
• PaceTWW.HuF.MillerAH.Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Br Behav Immun200721919
   PubMed Web of Science ®Google Scholar
• ParianteCM.MillerAH.Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry20014939140411274650
   PubMed Web of Science ®Google Scholar
• AntonijevicI.HPA axis and sleep: identifying subtypes of major depression. Stress200811152717853067
   PubMed Web of Science ®Google Scholar
• HeydendaelW.JacobsonL.Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res200812389310718761333
   PubMed Web of Science ®Google Scholar
• CarvalhoLA.ParianteCM.In vitro modulation of the glucocorticoid receptor by antidepressants. Stress20081141142419065455
   PubMed Web of Science ®Google Scholar
• SimonNG.GuillonC.FabioK.et al.Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Patents on CNS Drug Discovery20083779318537767
   PubMedGoogle Scholar
• iharaM.IdaI.YuukiN.et al.HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res200715524525617587554
   PubMed Web of Science ®Google Scholar
• KrausMR.Al-TaieO.ScheferA.PfersdorffM.LeschKP.ScheurlenM.Serotonin-1 A receptor gene (HTR1 A) variation predicts interferon-induced depression chronic hepatitis C. Gastroenterol200713212791286
   PubMed Web of Science ®Google Scholar
• CapuronL.RavaudA.NeveuPJ.MillerAH.MaesM.DantzerR.Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry2002746847312082564
   PubMed Web of Science ®Google Scholar
• GohierB.GoebJL.Rannou-DubasK.FouchardI.CalesP.GarreJB.Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry2003411511812872204
   PubMed Web of Science ®Google Scholar
• KoskinasJ.MerkourakiP.ManesisE.HadziyannisS.Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis Sci200220284288
   Google Scholar
• SmitsF.SmitsN.SchoeversR.DeegD.BeekmanA.CuijpersP.An epidemiological approach to depression prevention in old age. Am J Geriatr Psychiatry20081644445318515688
   PubMed Web of Science ®Google Scholar
• ColeMG.Evidence-based review of risk factors for geriatric depression and brief preventative interventions. Psychiatr Clin N Am200528785803
   PubMed Web of Science ®Google Scholar
• BrodatyH.GreenAA.KoscheraA.Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc20035165766412752841
   PubMed Web of Science ®Google Scholar
• ForsterA.YoungJ.Specialist nurse support for patients with stroke in the community: a randomized controlled trial. BMJ1996312164216468664717
   PubMed Web of Science ®Google Scholar
• NarushimaK.KosierTJ.RobinsonRG.Preventing poststroke depression: a 12-week double blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis200219029630312011609
   PubMed Web of Science ®Google Scholar
• RasmussenBB.LundeM.LoldrupPD.et al.A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients.Psychosornatics200344216221
   PubMed Web of Science ®Google Scholar
• AustinMP.Targeted group antenatal prevention of postnatal depression: a review. Acta Psychiatrica Scand200310724442250
   Web of Science ®Google Scholar
• DennisCLE.Preventing postpartum depression Part II: a critical view of nonbiological interventions. Can J Psychiatry20044952653815453102
   PubMed Web of Science ®Google Scholar
• ColeMG.Brief interventions to prevent depression in older subjects: a systematic review ofe feasibility and effectiveness. Am J Geriatr Psychiatry20081643544318515687
   PubMed Web of Science ®Google Scholar
• BarreraAZ.TorresLD.MunozRF.Prevention of depression: the state of the science at the beginning of the 21st century. Int Rev Psychiatry20081965567018092243
   PubMed Web of Science ®Google Scholar